A pharmaceutical company called Axsome Therapeutics has reached a legal agreement that will prevent other companies from selling cheaper, generic versions of its sleep disorder medication, Sunosi, until at least 2040. This decision comes after years of court battles with several generic drug manufacturers who had applied to sell their own versions of Sunosi. The agreement involves six companies, including Alkem Laboratories, Aurobindo Pharma, Hetero Labs, Hikma Pharmaceuticals, Sandoz, and Unichem, all of which had been sued by Axsome for attempting to produce generic Sunosi. The legal disputes started in 2023 when Axsome filed patent infringement lawsuits against these companies. Over time, five of the six companies settled their cases, agreeing not to launch their generic versions of Sunosi until either March 1, 2040, or September 1, 2040, depending on whether Axsome receives additional market protection for pediatric use. The last remaining company, Aurobindo Pharma, has now also agreed to settle, meaning no other legal challenges remain. Axsome must still submit this final agreement to U.S. regulatory authorities for approval. This outcome is seen as a major success for Axsome, with financial analysts noting that it could significantly benefit the company’s future sales and stock value. Sunosi was approved in 2019 for treating excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea. Axsome acquired the drug in 2022 from Jazz Pharmaceuticals, which sold it to Axsome for $53 million plus a royalty on future U.S. sales. Since then, Axsome has been working to expand Sunosi’s use beyond its original approved conditions. The company is currently studying Sunosi in clinical trials for conditions like attention deficit hyperactivity disorder (ADHD) in children and adults, major depressive disorder (MDD) with daytime sleepiness, binge eating disorder, and shift work disorder. In a recent trial for adults with ADHD, Sunosi showed a 45% average reduction in symptoms, leading to further studies in children and adolescents. Financial analysts believe Sunosi could become a highly successful drug, estimating it may generate up to $233 million in global sales by 2033 just based on its current approved uses. In 2025, Sunosi generated $124.8 million in sales for Axsome, contributing to the company’s total revenue of $638.5 million for the year, a 32% increase from 2024. So far in 2026, Sunosi has continued to grow, with sales of $33.9 million in the first quarter, a 34% increase compared to the same period in 2025. However, another medication from Axsome, called Auvelity, has been an even bigger financial success. Auvelity, approved in 2022, is used to treat major depressive disorder and has recently been approved for a new use in treating agitation related to Alzheimer’s disease. In 2025, Auvelity brought in $507.1 million in sales, and analysts predict it could eventually reach $8 billion in peak annual sales worldwide.